

Cerenis™

THERAPEUTICS

Press release

2019 Financial agenda

Toulouse, FRANCE, Lakeland, UNITED-STATES, January 23, 2019, 6.00 pm CET – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces its financial agenda for 2019.

Events	Date*
▪ Cash position as of December 31, 2018	January 24, 2019
▪ 2018 Annual Results and update on activity	January 24, 2019
▪ Cash position and revenue for Q1 2019	April 18, 2019
▪ Cash position and revenue for Q2 2019	July 25, 2019
▪ 2019 Half Year Results	September 10, 2019
▪ Cash position and revenue for Q3 2019	October 24, 2019

**Indicative dates which may be subject to change. With some exceptions, press releases are distributed after the financial markets closure.*

About CERENIS

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies. CERENIS' expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.



Cerenis
Cyrille Tupin
Deputy CEO
info@cerenis.com
+33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.eu
+33 (0)1 44 71 94 98